Seattle-based Alpine Immune Sciences, Inc. is a clinical-stage biopharmaceutical firm that specializes in researching and developing protein-based immunotherapies to treat diseases such as cancer and autoimmune/inflammatory disorders. The company boasts a robust product pipeline with three programs that are undergoing development. ALPN-101, an inducible T cell costimulator (ICOS)/cluster of differentiation 28 (CD28) antagonist program, targets autoimmune and inflammatory diseases. Meanwhile, ALPN-202 is a conditional CD28 costimulator and dual checkpoint inhibitor product that is designed for the treatment of cancer. Finally, ALPN-303 - a dual B cell cytokine antagonizing program - seeks to treat inflammatory and autoimmune diseases. This promising biopharmaceutical company has collaboration agreements with AbbVie Ireland Unlimited Company for the development of ALPN-101 and Adaptimmune Therapeutics PLC to produce next-generation SPEAR T cell products. The company's impressive 14-year journey began in 2007 when it was incorporated.